Αποτελέσματα Αναζήτησης
OVA1 is a test that measures five serum proteins and uses a menopause status to classify ovarian cancer risk in women with a mass. It is the first FDA-approved IVDMIA of proteomic biomarkers for ovarian cancer diagnosis.
Ova1Plus is a proprietary reflex process combining two FDA-cleared tests, Ova1 ®, leveraging high sensitivity, and Overa ®, leveraging high specificity, for patients with adnexal masses.
13 Οκτ 2009 · OVA1 Test is a biomarker panel that can help physicians assess the likelihood of malignancy of an ovarian tumor before surgery. It combines the results of five immunoassays and provides a numerical score based on a proprietary algorithm.
1 Αυγ 2018 · The OVA1 test is a blood test that assesses the levels of five proteins (including CA 125) that may change due to ovarian cancer. The OVA1 test is intended for women with an ovarian mass that requires surgical evaluation, but who have not yet been referred to a gynecologic oncologist.
1 Απρ 2012 · New biomarkers for ovarian cancer: OVA1 and ROMA in diagnosis. The optimal management of a woman with an ovarian adnexal mass remains a clinical challenge to obstetricians, gynecologists, and other providers who care for women.
22 Μαΐ 2023 · The OVA1 test evaluates five protein biomarkers (Apolipoprotein A1, Beta 2 microglobulin, CA125, Prealbumin and Transferrin) to determine ovarian cancer risk . OVA1 test results indicate low, high or intermediate risk.
10 Αυγ 2021 · OVA1 is a multivariate index assay that combines CA125 and four other serum proteins to assess the malignant risk of an adnexal mass. Objective: To evaluate the performance of OVA1 in a cohort of patients with low-risk serum CA125 values.
